Канада - английски - Health Canada

apotex inc - cefepime (cefepime hydrochloride) - powder for solution - 1g - cefepime (cefepime hydrochloride) 1g - fourth generation cephalosporins

Канада - английски - Health Canada

apotex inc - cefepime (cefepime hydrochloride) - powder for solution - 2g - cefepime (cefepime hydrochloride) 2g - fourth generation cephalosporins

Малта - английски - Malta Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - powder for solution for injection/infusion - cefepime 1 g - antibacterials for systemic use

Малта - английски - Malta Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - powder for solution for injection/infusion - cefepime 2 g - antibacterials for systemic use

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - cefepime dihydrochloride monohydrate 1.202 g equivalent to 1.0 g cefepime - powder for injection - 1 g - active: cefepime dihydrochloride monohydrate 1.202 g equivalent to 1.0 g cefepime excipient: arginine - maxipime is indicated in adults for the treatment of lower respiratory tract infections, including pneumonia and bronchitis, when caused by susceptible bacteria.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - cefepime dihydrochloride monohydrate 2.404 g equivalent to 2.0 g cefepime - powder for injection - 2 g - active: cefepime dihydrochloride monohydrate 2.404 g equivalent to 2.0 g cefepime excipient: arginine lactose monohydrate - maxipime is indicated in adults for the treatment of lower respiratory tract infections, including pneumonia and bronchitis, when caused by susceptible bacteria.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - cefepime dihydrochloride monohydrate 601mg equivalent to 500 mg cefepime - powder for injection - 500 mg - active: cefepime dihydrochloride monohydrate 601mg equivalent to 500 mg cefepime excipient: arginine lactose monohydrate - maxipime is indicated in adults for the treatment of lower respiratory tract infections, including pneumonia and bronchitis, when caused by susceptible bacteria.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefepime, quantity: 2000 mg - injection, powder for - excipient ingredients: arginine - adults:. cefepime is indicated in the treatment of the infections listed below when caused by susceptible bacteria.. - lower respiratory tract infections, including pneumonia and bronchitis;. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - intra-abdominal infections, including peritonitis and biliary tract infections;. - gynaecological infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. cefepime is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered.. paediatrics:. cefepime is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria. . - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empirical therapy with cefepime may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.. because of its broad spectrum of bactericidal activity against gram positive and gram negative bacteria, cefepime can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime. in patients who are at risk of mixed aerobic/ anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefepime, quantity: 1000 mg - injection, powder for - excipient ingredients: arginine - adults:. cefepime is indicated in the treatment of the infections listed below when caused by susceptible bacteria.. - lower respiratory tract infections, including pneumonia and bronchitis;. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - intra-abdominal infections, including peritonitis and biliary tract infections;. - gynaecological infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. cefepime is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered.. paediatrics:. cefepime is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria. . - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empirical therapy with cefepime may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.. because of its broad spectrum of bactericidal activity against gram positive and gram negative bacteria, cefepime can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime. in patients who are at risk of mixed aerobic/ anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.

Малайзия - английски - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaforte (malaysia) sdn. bhd. - cefepime hydrochloride monohydrate -